Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMade Tech Regulatory News (MTEC)

Share Price Information for Made Tech (MTEC)

Share Price is delayed by 15 minutes
Get Live Data
39.25    1.00 (2.61%)
Bid:
38.50
Ask:
40.00
Spread: 1.50 (3.896%)
Market Cap: £58.60m
MTEC Live PriceLast checked at - London Stock Exchange

Intraday Made Tech Share Chart

Trading Statement

10 Dec 2025 07:00

RNS Number : 9157K
Made Tech Group PLC
10 December 2025
 

 

10 December 2025

 

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

 

MADE TECH GROUP PLC

("Made Tech", the "Group" or the "Company")

 

FIRST HALF TRADING UPDATE

Trading significantly ahead of expectations

 

Made Tech, a leading provider of digital, data and technology services to the UK public sector, is pleased to announce a trading update for the 6 months ended 30 November 2025 ("H1 FY26").

 

Revenue for H1 FY26 was c.£27.7 million (H1 FY25: £21.8 million), representing a year-on-year increase of c.27% following good Sales Bookings1 momentum in the second half of FY25. 

 

Adjusted EBITDA2 for H1 is expected to be c.£2.4 million (H1 FY25: £1.8 million), c.33% up on the equivalent prior year period. This represents an increase in margin from 8.2% to c.8.7%, a result of operational efficiencies, offset by a higher than target contractor base.

 

Net cash as at 30 November 2025 was £11.9 million (FY25: £10.4 million; H1 FY25: £9.1 million), reflecting the continuing strong operating cash flow conversion of the business. Made Tech remains debt-free.

 

As at 30 November 2025 Contracted Backlog3 was c.£74.0 million (FY25: £92.2 million; H1 FY25: £80.8 million) which provides good contractual coverage for the remainder of FY26 and into FY27. Sales bookings for H1 FY26 were softer than the strong prior year performance but the Sales Booking pipeline remains very active with a number of opportunities expected to increase the Contracted Backlog position in H2.

 

As a result of the strong trading performance in the first half of the year, the Board now expects trading for FY26 to be significantly ahead of current market expectations4, with revenue expected to be c.10% higher and Adjusted EBITDA margins increasing, reflecting improved operational gearing. The Group looks forward to announcing its Interim results for the 6 month period ended 30 November 2025 in February 2026.

 

Rory MacDonald, Chief Executive Officer, commented: 

 

"The first half of 2026 has been an exceptionally strong period for both revenue and Adjusted EBITDA, building on the momentum seen in FY25. Robust cash generation has further improved our balance sheet position and the strategic optionality this provides. Our near-term focus remains on sales pipeline conversion and adding to our already solid Contracted Backlog position, giving us good visibility into FY27.

 

The UK Government has emphasised the significant role technology will play in delivering its priorities, and we believe the Group continues to be well-positioned to capitalise on these opportunities. Consequently, we remain optimistic and confident in our outlook."

 

 Notes:

 

 All financials are based on unaudited figures.

 

1

Sales Bookings represent the total value of sales contracts awarded in the Period, to be delivered in FY26-FY30. Net Sales Bookings includes the value of sales contracts previously recognised that lapsed during the Period.

2

Adjusted EBITDA has been adjusted for the exclusion of depreciation, amortisation, impairments, exceptional items and share-based payment charge.

3

Contracted Backlog is the value of contracted revenue that has not yet been recognised. 

4

Based on the latest published equity research, the Company understands current market consensus for the year ended 31 May 2026 (FY26) to be revenue of £50.1m, Adjusted EBITDA of £3.9m and cash of £13.1m, and for the year ended 31 May 2027 (FY27) to be revenue of £55.1m, Adjusted EBITDA of £4.4m and cash of £16.1m.

 

 Enquiries:

 

Made Tech Group plc

Rory MacDonald, CEO

Neil Elton, CFO

Email: investor-relations@madetech.com

Canaccord Genuity Limited (Nominated Adviser & Broker)

Simon Bridges / Harry Gooden / Andrew Potts / Elizabeth Halley-Stott

Tel: +44 (0) 20 7523 8000

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTDBBDDCDGDGUC
12
Date   Source Headline
2nd May 20237:00 amRNSTrading Update
17th Apr 20237:12 amRNSTR1
23rd Feb 20237:05 amRNSLTIP Update and PDMR Dealing
23rd Feb 20237:00 amRNSHalf Year Results
2nd Feb 202311:05 amRNSSecond Price Monitoring Extn
2nd Feb 202311:00 amRNSPrice Monitoring Extension
1st Feb 20234:40 pmRNSSecond Price Monitoring Extn
1st Feb 20234:35 pmRNSPrice Monitoring Extension
1st Feb 20232:05 pmRNSSecond Price Monitoring Extn
1st Feb 20232:00 pmRNSPrice Monitoring Extension
1st Feb 20237:00 amRNSTrading Update and Notice of Results
13th Jan 20234:40 pmRNSSecond Price Monitoring Extn
13th Jan 20234:35 pmRNSPrice Monitoring Extension
12th Jan 20232:05 pmRNSSecond Price Monitoring Extn
12th Jan 20232:00 pmRNSPrice Monitoring Extension
15th Nov 202211:05 amRNSSecond Price Monitoring Extn
15th Nov 202211:00 amRNSPrice Monitoring Extension
15th Nov 20227:00 amRNSNew £10m contract with the Home Office
19th Oct 20225:17 pmRNSResult of AGM, Deferred Shares & Issue of Equity
29th Sep 20227:00 amRNSIssue of New Ordinary Shares to EBT
23rd Sep 20224:31 pmRNSNotice of AGM and Posting of Annual Report 2022
12th Sep 20227:00 amRNSAudited Final Results
26th Aug 20229:00 amRNSPrice Monitoring Extension
26th Aug 20227:00 amRNSNotice of Final Results and Online Presentations
19th Aug 20227:00 amRNSTrading Update
1st Jul 20227:00 amRNSMet Office Contract
24th Jun 20224:41 pmRNSSecond Price Monitoring Extn
24th Jun 20224:36 pmRNSPrice Monitoring Extension
2nd Mar 20224:40 pmRNSSecond Price Monitoring Extn
2nd Mar 20224:35 pmRNSPrice Monitoring Extension
2nd Mar 202210:56 amRNSDirector Share Purchase
28th Feb 20224:41 pmRNSSecond Price Monitoring Extn
28th Feb 20224:37 pmRNSPrice Monitoring Extension
28th Feb 202211:06 amRNSSecond Price Monitoring Extn
28th Feb 202211:00 amRNSPrice Monitoring Extension
28th Feb 20229:05 amRNSSecond Price Monitoring Extn
28th Feb 20229:00 amRNSPrice Monitoring Extension
28th Feb 20227:00 amRNSMajor new contract with NHS Digital
28th Feb 20227:00 amRNSMade Tech Group Interim Results
18th Feb 20227:00 amRNSNotice of Results
15th Dec 20217:00 amRNSTrading Update and Notice of Interim Results
13th Oct 20217:00 amRNSNew Contract Win
5th Oct 20213:29 pmRNSHolding(s) in Company
30th Sep 20214:41 pmRNSSecond Price Monitoring Extn
30th Sep 20214:36 pmRNSPrice Monitoring Extension
30th Sep 20219:00 amRNSPrice Monitoring Extension
30th Sep 20217:00 amRNSFirst Day of Dealings
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.